• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Importance Among patients undergoing percutaneous coronary intervention (PCI), it
remains unclear whether the treatment efficacy of P2Y 12 inhibitor monotherapy after a short …

Objective To provide a quantitative comparison between myocardial revascularization
(REVASC) and optimal medical treatment (OMT) alone in patients with chronic coronary …

Despite improvements in clinical outcomes following acute myocardial infarction, mortality
remains high, especially in patients with severely reduced left ventricular ejection fraction …

Importance The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute
coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains …

Antithrombotic therapy represents the cornerstone of the pharmacological treatment in
patients with acute coronary syndrome (ACS). The optimal combination and duration of …

Importance Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period
of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet …

Antithrombotic therapy after cardiac percutaneous interventions is key for the prevention of
thrombotic events but is inevitably associated with increased bleeding, proportional to the …

Background It remains unclear whether clopidogrel is better suited than aspirin as the long-
term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous …

In cancer, activation of platelets by tumor cells is critical to disease progression.
Development of precise antiplatelet targeting may improve outcomes from anticancer …